Table 1

Patient demographic and clinical characteristics in the QUEST-RA Study by country
Country
 Sites
 Patients
 Female, percentage
 Age, years
 Disease duration, years
 DMARD delay, months
 RF+, percentage
 Smoking now, percentage
 DAS28
 SJC28
 ESR
 Pain
 Patient global
 HAQ
 Taking now, percentage






























Pred
 MTX
 Any biologic
Netherlands
 3
 317
 66.3
 59.2
 9.2
 6.0
 68.8
 22.9
 3.1
 1.0
 15.0
 2.5
 2.7
 0.8
 16.1
 74.1
 19.6
Finland
 3
 304
 72.4
 58.5
 13.5
 7.0
 74.8
 15.5
 3.3
 1.0
 13.0
 2.8
 2.8
 0.6
 51.3
 61.5
 12.5
USA
 3
 301
 72.9
 57.5
 9.3
 9.0
 70.9
 20.5
 3.3
 2.0
 14.0
 3.2
 2.6
 0.6
 60.1
 71.8
 27.6
Greece
 3
 300
 75.7
 58.1
 11.8
 7.0
 52.1
 15.8
 3.4
 0.0
 23.0
 2.3
 2.0
 0.3
 70.7
 71.3
 47.0
Denmark
 3
 301
 76.7
 57.8
 12.0
 11.0
 73.3
 31.6
 3.4
 1.0
 14.0
 2.6
 2.8
 0.6
 14.6
 71.1
 21.3
Spain
 3
 302
 73.5
 59.8
 10.6
 14.0
 72.5
 17.8
 3.5
 1.0
 17.0
 3.1
 3.6
 0.9
 46.7
 56.3
 23.2
France
 4
 389
 77.9
 55.3
 12.8
 8.0
 75.3
 19.1
 3.7
 1.0
 16.0
 3.9
 3.6
 0.9
 60.9
 57.1
 44.2
Sweden
 3
 260
 71.8
 59.4
 12.5
 12.0
 81.6
 19.2
 3.8
 2.0
 19.0
 3.3
 3.3
 0.9
 41.2
 65.8
 26.9
UK
 3
 145
 77.9
 59.6
 15.0
 16.0
 81.4
 19.4
 4.0
 1.0
 19.0
 4.1
 3.6
 0.9
 28.3
 70.3
 14.5
Ireland
 3
 240
 64.3
 56.4
 11.3
 11.0
 79.6
 24.6
 4.1
 3.0
 18.0
 3.4
 2.9
 0.8
 31.7
 71.7
 32.1
Canada
 1
 100
 78.8
 57.9
 12.4
 11.0
 82.8
 30.0
 4.1
 2.0
 21.0
 4.6
 4.0
 1.0
 25.0
 49.0
 23.0
Turkey
 3
 309
 85.6
 52.2
 11.6
 12.0
 67.6
 14.1
 4.2
 0.0
 30.0
 4.2
 4.6
 0.9
 57.3
 69.3
 5.8
Brazil
 3
 115
 88.6
 52.3
 8.5
 8.0
 79.6
 13.3
 4.2
 3.0
 28.0
 3.2
 3.5
 0.6
 53.9
 80.0
 25.2
UAE
 2
 199
 85.8
 45.3
 6.4
 11.7
 75.4
 6.3
 4.3
 3.0
 23.5
 3.7
 2.8
 0.6
 35.2
 53.3
 7.5
Germany
 3
 225
 83.6
 58.8
 13.4
 15.0
 60.9
 13.5
 4.4
 3.0
 20.0
 5.0
 4.9
 0.8
 26.7
 45.8
 22.7
Italy
 4
 336
 78.2
 61.0
 10.5
 9.0
 71.4
 15.9
 4.5
 2.0
 28.0
 4.9
 5.0
 1.0
 51.8
 53.3
 12.5
Estonia
 3
 168
 85.5
 55.8
 11.8
 12.0
 68.1
 14.0
 4.7
 4.0
 24.0
 4.3
 4.8
 1.1
 43.5
 53.6
 0.6
Russia
 3
 73
 84.5
 54.2
 6.2
 10.0
 74.6
 15.4
 5.0
 5.0
 24.0
 3.6
 4.5
 1.1
 38.4
 46.6
 16.4
Hungary
 3
 153
 87.4
 57.9
 12.6
 12.0
 92.8
 25.3
 5.1
 5.0
 26.0
 5.2
 5.1
 1.4
 36.6
 62.7
 12.4
Latvia
 1
 79
 79.7
 53.2
 13.2
 32.1
 84.6
 19.2
 5.2
 4.0
 26.0
 5.1
 5.7
 1.4
 63.3
 70.9
 21.5
Poland
 7
 642
 86.7
 53.2
 11.5
 4.0
 70.3
 11.9
 5.3
 6.0
 31.0
 5.0
 4.8
 1.4
 58.9
 65.0
 6.1
Argentina
 2
 246
 90.2
 51.4
 9.9
 13.0
 90.5
 21.4
 5.3
 9.0
 30.0
 5.0
 4.7
 1.0
 63.4
 48.8
 2.8
Lithuania
 2
 300
 82.9
 54.1
 10.7
 15.0
 78.4
 7.1
 5.5
 3.0
 29.0
 5.2
 5.3
 1.4
 82.7
 55.7
 9.3
Serbia
 1
 100
 88.0
 59.2
 10.1
 11.1
 71.4
 18.4
 5.9
 6.0
 28.0
 5.1
 5.3
 1.6
 54.0
 54.0
 0.0
Kosovo
 1
 100
 84.0
 55.0
 7.8
 3.0
 80.6
 10.4
 6.0
 6.0
 45.0
 5.1
 5.0
 1.6
 90.0
 71.0
 1.0
Total
 70
 6,004
 79.2
 56.2
 11.2
 10.0
 73.6
 17.4
 4.2
 2.0
 22.0
 4.1
 4.2
 0.9
 49.1
 62.5
 18.3

Mean values are presented for age, disease duration, and disease activity score using 28 joint counts (DAS28). Median values are presented for other continuous variables. DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; Pred, prednisone; QUEST-RA, Quantitative Standard Monitoring of Rheumatoid Arthritis; RF, rheumatoid factor; SJC, swollen joint count; UAE, United Arab Emirates.

Sokka et al. Arthritis Research & Therapy 2009 11:R7   doi:10.1186/ar2591

Open Data